5-羟基-3-(1H)吲唑甲醛 | 882803-11-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 5-羟基-3-(1H)吲唑甲醛
• 英文名称: 5-hydroxy-1H-indazole-3-carbaldehyde
• 英文别名: 5-hydroxy-2H-indazole-3-carbaldehyde
• CAS: 882803-11-4
• 化学式: C₈H₆N₂O₂
• mdl: MFCD07781438
• 分子量: 162.148
• InChiKey: VSEHFSVJKJQICE-UHFFFAOYSA-N

物化性质

• 沸点：
  451.0±25.0 °C(Predicted)
• 密度：
  1.541±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-羟基-3-(1H)吲唑甲醛 在 哌啶 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 tert-butyl (Z)-4-[(6-methoxy-2-{[5-(2-morpholinoethoxy)-1H-indazol-3-yl]methylene}-3-oxo-2,3-dihydrobenzofuran-7-yl)methyl]piperazine-1-carboxylate
  参考文献：
  名称：

  ANTICANCER AGENT

  摘要：

  公开号：

  EP2565192B9
• 作为产物：
  描述：

  5-羟基吲哚 在 吡啶 、 盐酸 、 甲醇 、 potassium carbonate 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 19.5h， 生成 5-羟基-3-(1H)吲唑甲醛
  参考文献：
  名称：

  ANTICANCER AGENT

  摘要：

  公开号：

  EP2565192B9

文献信息

• Amine Compounds
  申请人：Ohmori Yutaka

  公开号：US20080200535A1

  公开（公告）日：2008-08-21

  There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

  提供了一种化合物，具有抑制免疫反应并减少不良药物反应的活性，该化合物在化疗中用于预防或治疗各种自身免疫性疾病，包括系统性红斑狼疮、慢性类风湿关节炎、I型糖尿病、炎症性肠病、胆汁性肝硬化、葡萄膜炎、多发性硬化或其他疾病，慢性炎症性疾病，癌症，淋巴瘤或白血病，器官或组织移植的抗性或对移植的排斥。提供了具有S1P1/Edg1受体激动剂作用的新型胺类化合物，可能是这些化合物的立体异构体或消旋体，或这些化合物、立体异构体或消旋体的药理学上可接受的盐、水合物或溶剂合物，或这些化合物、立体异构体、消旋体、盐、水合物或溶剂的前药。
• Indazole benzimidazole compounds
  申请人：Jansen M. Johanna

  公开号：US20060079564A1

  公开（公告）日：2006-04-13

  Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.

  提供具有结构I的有机化合物，其中变量具有所述值。一种抑制患者中c-ABL的方法包括向患者投与结构I的化合物，化合物的互变异构体，化合物的药学上可接受的盐或互变异构体的药学上可接受的盐的有效量。
• INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF
  申请人：XIE Wenge

  公开号：US20090088437A1

  公开（公告）日：2009-04-02

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明涉及尼古丁乙酰胆碱受体（nAChR）配体、nAChR的激活以及与缺陷或功能失调的尼古丁乙酰胆碱受体相关的疾病状态的治疗，特别是与大脑相关的疾病状态。此外，本发明涉及新型化合物，例如吲哚、1H-吲哚唑、1,2-苯并异噁唑和1,2-苯并异硫噻唑，它们作为α7 nAChR亚型的配体，制备这种化合物的方法，含有这种化合物的组合物以及使用这种化合物的方法。
• The Serotonin 5-HT4 Receptor. 2. Structure-Activity Studies of the Indole Carbazimidamide Class of Agonists
  作者：Karl-Heinz Buchheit、Rainer Gamse、Rudolf Giger、Daniel Hoyer、Francois Klein、Edgar Kloeppner、Hans-Juergen Pfannkuche、Henri Mattes

  DOI：10.1021/jm00013a010

  日期：1995.6

  A number of substituted indole carbazimidamides were prepared and evaluated as 5-HT4 receptor agonists by using the isolated field-stimulated guinea pig ileum preparation. Their selectivity for the 5-HT4 receptor was established by examining their affinity for other 5-HT receptors using radioligand-binding techniques. Several selective and highly potent full as well as partial agonists emerged from this study. For example, 1b,d were found to be the most potent, full 5-HT4 receptor agonists described so far (EC(50) = 0.5 and 0.8 nM, respectively), being 6 and 4 times more potent than serotonin itself. On the other hand, 5b and 1h appeared as partial 5-HT4 receptor agonists in the nonstimulated guinea pig ileum preparation with potencies, evaluated against serotonin action, respectively similar (5b, K-i = 12 nM) to and 300-fold higher (1h, K-i = 0.04 nM) than serotonin.
• US7396833B2
  申请人：——

  公开号：US7396833B2

  公开（公告）日：2008-07-08